Project Grant R01EY037225
Award Date
7/1/25
Completion Date
4/30/30
Dollars Obligated
$603K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research to investigate the role of myeloid cells in axon damage and degeneration associated with glaucoma. The research aims to determine whether NAD+-boosting interventions, which have shown promise in promoting axon protection, work through an anti-inflammatory mechanism by inhibiting myeloid cell recruitment. The award provides $423,767.00 over a 2-year period...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
The National Eye Institute (NEI), through its Vision Research federal grant program (CFDA 93.867), awarded a $679,159 Project Grant to The Schepens Eye Research Institute, Inc. in Boston, Massachusetts. The grant, awarded on May 1, 2025, supports research aimed at understanding how aging and elevated intraocular pressure (IOP) contribute to the development of glaucoma and impact retinal ganglion cells (RGCs). The research project will investigate the transcriptomic changes in RGCs due to aging...
This Project Grant award of $1,593,473.00, provided by the National Eye Institute under the Vision Research program (CFDA 93.867), will support a multiomic analysis of preclinical biomarkers for primary open-angle glaucoma (POAG). The study aims to analyze proteomic and metabolomic markers, and their interactions with genetic predisposition, to advance understanding of POAG pathophysiology. Researchers will use plasma samples from a nested case-control group within ongoing prospective cohorts,...
This federal Project Grant award of $618,088 from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) will support research to investigate the role of mitochondrial DNA (mtDNA) and the DNA/RNA sensor ZBP1 in retinal neurodegeneration associated with glaucoma. The research team from the University of Texas Medical Branch at Galveston will use novel ZBP1 conditional knockout or overexpression mouse models, in vivo tracking of extracellular vesicles, and...
This federal Project Grant award, totaling $496,633, was awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867). The grant supports a research project at Duke University to investigate the role of glypicans, specifically glypican-4 (GPC4), in trabecular meshwork function, intraocular pressure regulation, and the development of glaucoma. The project aims to uncover the molecular mechanisms by which augmented GPC4 expression and secretion may dysregulate Wnt...
This Project Grant award of $526,841 from the National Eye Institute (CFDA 93.867 - Vision Research) will support research at Vanderbilt University Medical Center (VUMC) to investigate the role of cGMP signaling in glaucomatous neurodegeneration. The goal is to probe the mechanisms of retinal ganglion cell (RGC) degeneration in glaucoma, a leading cause of irreversible blindness, in order to identify novel therapeutic targets to protect and potentially restore vision. The research will focus...
The National Eye Institute (NEI) awarded a $568,122 Project Grant under the Vision Research program (CFDA 93.867) to Baylor College of Medicine to conduct research on the role of vascular ligands and neurovascular dysfunction in glaucoma. The project aims to systematically identify endothelial cell-specific ligands that can modulate retinal ganglion cell function and survival in glaucoma, with the goal of developing novel neuroprotective therapies. The award period runs from July 1, 2025 to...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of neural activity in improving retinal ganglion cell (RGC) replacement therapies for glaucoma. The $132,597 award to The Schepens Eye Research Institute, Inc. aims to: 1) characterize retinal remodeling following RGC inactivation, and 2) determine if inhibiting host neural activity can enhance the structural and functional integration...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), will fund research to understand the genetic causes of inherited retinal degenerations (IRDs), a group of rare blinding diseases. The $1,369,782 award to the Massachusetts Eye and Ear Infirmary will support two key research aims: Developing a high-throughput splicing assay to identify rare coding and non-coding variants that lead to splicing defects and contribute to the...